Abstract 3753
Background
The advanced practice nurse (APN), with ability to apply evidence in an integrated framework, assumes new roles and acts as benchmark for patient and other professionals. In the last two decades, nurses have developed new advanced roles. There is international experience of the implementation for new model, and organizational ways by integrating and integrate interventions for EPA. High positive results in coordinating services and multidisciplinary teams, facilitate continuity of care resulting better quality of life and greater satisfaction for patients.
Methods
Descriptive study with patients treated in the functional unit of the Catalan Institute of Oncology in year 2018. After literature review on roles for nurses in lung cancer, we review number of interventions and activity carried out by EPA.
Results
A total of 589 first cases lung cancer started their first treatment. Nurse visited 93.2% of them in the Lung Functional Unit (LFU). Type of treatment; surgical 26.41%, palliative chemotherapy 11.83%, concomitant chemo+ radiotherapy in 11.65%, immunotherapy 4.19%, TKis 3.1%, sequential chemo+radiotherapy 3.2%, neoadjuvant chemo 1.58%, chemo+immunotherapy 0.27%, neoadjuvant chemo+radiotherapy+surgery in 0.15% and the rest 37.62% with supportive or palliative treatment. A total of 2563 visits by nurse, 21.42% were first visits, 73.23% patients with active treatment and 4.7% that have completed the treatment but with some toxicity. A total of 3935 phone calls were attended by nurses, of which 81.19% were patients who made calls and 18.80% were nurses on phone for control. Derivation was resulting to emergency for 5.13% of patients. 87.79% cases presented in Lung tumors board needed coordination for visits and for complementary proves.
Conclusions
Incorporate the EPA in the multidisciplinary care helps to minimize complications, to improve coordination and avoid deviations of the care process. Key activities were: health education to patient and family on care and self-care, improve the compression of the disease, the treatment and the process, strengthen information, minimize problems and improve resources for the care process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract